Smoker's Cough

Novartis Seeking Approval for Medication to Treat 'Smoker's Cough'

Medicine & Technology Novartis AG, a Swiss drug maker, is seeking U.S. regulatory approval for two new drugs designed to treat chronic obstructive pulmonary disease (COPD), otherwise known as "smoker's cough". Approval of the drugs could generate an additional $1.4 billion for the company, while helping chronic smokers breathe a little clearer in the process.

Recommended Stories

Real Time Analytics